Ayse Begum Ceviz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ayse Begum Ceviz has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hulya Yilmaz-Aydogan
Istanbul Universitesi
6 shared publications - Oguz Ozturk
Istanbul Universitesi
5 shared publications - Allison Pinar Eronat
Haliç Üniversitesi
4 shared publications - Tulin Ozturk
İstanbul Üniversitesi-Cerrahpaşa
3 shared publications - Gonca Candan
Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
2 shared publications - Gulcin Ozkara
Bezmialem Vakif University
2 shared publications
Latest Publications
- 5 March 2026
- Published by ACG Publications in Records of Natural Products
- Vol. 20 (4) , 1
A mixture of potent polyphenolic anticarcinogens: Microarray analysis of their efficacy in MCF-7 and MCF-10A cell lines
Polyphenols are abundantly available through diet and show great promise with their safe use against cancer. In our previous studies, we have shown cytotoxic effects of more than 30 polyphenols in breast cancer. In this study, we have aimed to investigate the effects of various polyphenols upon MCF-7 breast cancer and MCF-10A normal epithelial cells. To this end, we have designed a polyphenolic mixture based on the most effective concentrations of seven compounds, which is a first according to literature in terms of polyphenolic combination studies. Cell proliferation experiments were executed utilizing WST-1 and apoptotic status by Annexin V-PI. After determining most effective concentrations, we operated whole genome microarray analysis. Based on microarray data, the best effective concentration for both cell lines is 75% of polyphenolic mixture. In MCF-7 cell line, this dosage induced in down regulation of cell cycle, cell division, DNA repair and some genes linked to breast cancer. In contrast, no remarkable effect was observed in MCF-10A cell line. The designed polyphenolic mixture was demonstrated to inhibit breast cell division in multiple pathways. Our findings on cell division in MCF-7 cell line were found similarly with the study based on polyphenol-rich propolis which inhibited cell division remarkably in SK-BR-3 cells. This mixture, which is shown to have highly effective anticarcinogenic effects, can be considered as a prototype of natural prescription design for our future research.
- 5 March 2026
- Published by ACG Publications in Records of Natural Products
- Vol. 20 (4) , 1
A mixture of potent polyphenolic anticarcinogens: Microarray analysis of their efficacy in MCF-7 and MCF-10A cell lines
Polyphenols are abundantly available through diet and show great promise with their safe use against cancer. In our previous studies, we have shown cytotoxic effects of more than 30 polyphenols in breast cancer. In this study, we have aimed to investigate the effects of various polyphenols upon MCF-7 breast cancer and MCF-10A normal epithelial cells. To this end, we have designed a polyphenolic mixture based on the most effective concentrations of seven compounds, which is a first according to literature in terms of polyphenolic combination studies. Cell proliferation experiments were executed utilizing WST-1 and apoptotic status by Annexin V-PI. After determining most effective concentrations, we operated whole genome microarray analysis. Based on microarray data, the best effective concentration for both cell lines is 75% of polyphenolic mixture. In MCF-7 cell line, this dosage induced in down regulation of cell cycle, cell division, DNA repair and some genes linked to breast cancer. In contrast, no remarkable effect was observed in MCF-10A cell line. The designed polyphenolic mixture was demonstrated to inhibit breast cell division in multiple pathways. Our findings on cell division in MCF-7 cell line were found similarly with the study based on polyphenol-rich propolis which inhibited cell division remarkably in SK-BR-3 cells. This mixture, which is shown to have highly effective anticarcinogenic effects, can be considered as a prototype of natural prescription design for our future research.
- 17 June 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (2) , 2671-2696
Predicting Risk of Lymph Node Metastasis in Papillary Thyroid Cancer Using miRNAs and Clinicopathological Features
This study investigates potential prognostic values in models created with clinicopathological features and expression profiles of miRNAs known for their critical roles in papillary thyroid carcinoma (PTC) for lymph node metastasis (LNM) in PTC cases. Forty-seven lymph node-metastatic PTC patients and 46 non-metastatic patients were included. Using RT-PCR, miR-21, miR-146b, miR-221, and miR-222 expression was analyzed in carcinoma tissues and metastatic lymph nodes of the same PTC patients and carcinoma tissues of non-metastatic PTC patients. MiR-146b (p < 0.001) and miR-221 (p = 0.009) were overexpressed in metastatic PTCs compared to non-metastatic PTCs. The miRNA expression profiles were similar in the lymph nodes and primary cancer of metastatic PTCs. In the presence of larger tumors (> 1 cm) in metastatic PTCs, miR-146b and miR221 were overexpressed in the tumor tissue (p = 0.036), while miR-222 was overexpressed in metastatic lymph nodes (p = 0.035). miR-146b was also upregulated in lack of peritumoral lymphocyte infiltration (p = 0.006). In conclusion, our findings suggest that the overexpression of miR-146b and miR-221 in PTC tissues may be associated with lymph node metastasis and a poorer prognosis. Furthermore, the presence of larger tumors and increased levels of intratumoral fibrosis in non-metastatic PTC patients could indicate a poor prognosis. Graphical Abstract
- 17 June 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (2) , 2671-2696
Predicting Risk of Lymph Node Metastasis in Papillary Thyroid Cancer Using miRNAs and Clinicopathological Features
This study investigates potential prognostic values in models created with clinicopathological features and expression profiles of miRNAs known for their critical roles in papillary thyroid carcinoma (PTC) for lymph node metastasis (LNM) in PTC cases. Forty-seven lymph node-metastatic PTC patients and 46 non-metastatic patients were included. Using RT-PCR, miR-21, miR-146b, miR-221, and miR-222 expression was analyzed in carcinoma tissues and metastatic lymph nodes of the same PTC patients and carcinoma tissues of non-metastatic PTC patients. MiR-146b (p < 0.001) and miR-221 (p = 0.009) were overexpressed in metastatic PTCs compared to non-metastatic PTCs. The miRNA expression profiles were similar in the lymph nodes and primary cancer of metastatic PTCs. In the presence of larger tumors (> 1 cm) in metastatic PTCs, miR-146b and miR221 were overexpressed in the tumor tissue (p = 0.036), while miR-222 was overexpressed in metastatic lymph nodes (p = 0.035). miR-146b was also upregulated in lack of peritumoral lymphocyte infiltration (p = 0.006). In conclusion, our findings suggest that the overexpression of miR-146b and miR-221 in PTC tissues may be associated with lymph node metastasis and a poorer prognosis. Furthermore, the presence of larger tumors and increased levels of intratumoral fibrosis in non-metastatic PTC patients could indicate a poor prognosis. Graphical Abstract
- 25 March 2024
- Published by ACG Publications in Records of Natural Products
- Vol. 18 (2) , 201-211
Whole Genome Expression Analysis Identifies Multiple Targeted Integrative Effects of Polyphenol-Rich Propolis on HER-2-Positive Breast Cancer Cell
Natural products have been focused by researchers due to their important anticarcinogenic characteristics in the treatment of cancer with the slightest side effects possible. Propolis is one of the most prominent candidates among these natural products in terms of its anticancer features. In this study we aim to research the effects of Anatolian propolis on ER/PR-, HER-2/neu+ human breast cancer cell line SK-BR-3 with intent to clarify the molecular mechanism propolis in HER+ breast cancers in overview of whole genomic expression for the first time via a microarray experiment. Afterwards, microarray data was validated via real time PCR with the selected genes. After performing bioinformatic analysis via GeneSpring Software and String analysis, a 50 µg/mL dose of propolis affected several pathways of HER-2 positive breast cancer cells including cell cycle, DNA repair and apoptosis especially at 48th hour exposure. In contrast, after exposure to 50 µg/mL dose of propolis, up-regulated genes were detected at diverse pathways such as immune response, cell migration regulation, organization of cell-cell adhesion, etc. For this reason, we proposed that polyphenol-rich propolis can be used in the treatment of HER-2 positive breast cancer with characteristics of less toxic than the current treatment methods
- 25 March 2024
- Published by ACG Publications in Records of Natural Products
- Vol. 18 (2) , 201-211
Whole Genome Expression Analysis Identifies Multiple Targeted Integrative Effects of Polyphenol-Rich Propolis on HER-2-Positive Breast Cancer Cell
Natural products have been focused by researchers due to their important anticarcinogenic characteristics in the treatment of cancer with the slightest side effects possible. Propolis is one of the most prominent candidates among these natural products in terms of its anticancer features. In this study we aim to research the effects of Anatolian propolis on ER/PR-, HER-2/neu+ human breast cancer cell line SK-BR-3 with intent to clarify the molecular mechanism propolis in HER+ breast cancers in overview of whole genomic expression for the first time via a microarray experiment. Afterwards, microarray data was validated via real time PCR with the selected genes. After performing bioinformatic analysis via GeneSpring Software and String analysis, a 50 µg/mL dose of propolis affected several pathways of HER-2 positive breast cancer cells including cell cycle, DNA repair and apoptosis especially at 48th hour exposure. In contrast, after exposure to 50 µg/mL dose of propolis, up-regulated genes were detected at diverse pathways such as immune response, cell migration regulation, organization of cell-cell adhesion, etc. For this reason, we proposed that polyphenol-rich propolis can be used in the treatment of HER-2 positive breast cancer with characteristics of less toxic than the current treatment methods
- 15 February 2024
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 44 (3) , 185-205
Unusual effects of PCSK9 E670G (rs505151) variation in patients with in-stent restenosis: Variable effects on restenosis risk according to concomitant chronic conditions
Recent reports showing that neo-atherosclerosis formation in stented coronary artery is characterized by the accumulation of lipid-laden macrophages within the neointima has strengthened the possibility that elevated low-density lipoprotein (LDL)-cholesterol may be a risk factor for in-stent restenosis (ISR). Protein Convertase Subtilisin/Kexin-9 (PCSK9) protein plays an important role in cholesterol metabolism by degrading of LDL receptors. The gain-of-function E670G (rs505151) mutation of the PCSK9 gene is a well-known genetic risk factor for hypercholesterolemia. This study evaluated for the first time the association of the E670G variation with the serum lipids, PCSK9 levels and concomitant diseases on the ISR risk. The study included 109 ISR, and 82 Non-ISR patients, based on the results of coronary angiography. Genotypes were determined using the real-time PCR and serum PCSK9 levels were measured by ELISA technique. The rare G allele of PCSK9 E670G (p < 0.05), hyperlipidemia (HL) (p < 0.001), and type 2 diabetes (T2DM) (p < 0.01) were associated with increased risk for ISR. In hyperlipidemic conditions, the E670G-G allele was associated with hypercholesterolemia and a higher risk of ISR (p < 0.001), while the E670G-AA genotype has been associated with a high prevalence of T2DM and hypertension. In addition, diabetic ISRs had higher serum PCSK9 levels (p < 0.05) and the E670G-AA genotype was associated with increased levels of diabetes markers. Our results indicated that the unusual effects of both G allele and AA genotype of the PCSK9 E670G variation may be involved in the risk of ISR in association with concomitant metabolic diseases.
- 15 February 2024
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 44 (3) , 185-205
Unusual effects of PCSK9 E670G (rs505151) variation in patients with in-stent restenosis: Variable effects on restenosis risk according to concomitant chronic conditions
Recent reports showing that neo-atherosclerosis formation in stented coronary artery is characterized by the accumulation of lipid-laden macrophages within the neointima has strengthened the possibility that elevated low-density lipoprotein (LDL)-cholesterol may be a risk factor for in-stent restenosis (ISR). Protein Convertase Subtilisin/Kexin-9 (PCSK9) protein plays an important role in cholesterol metabolism by degrading of LDL receptors. The gain-of-function E670G (rs505151) mutation of the PCSK9 gene is a well-known genetic risk factor for hypercholesterolemia. This study evaluated for the first time the association of the E670G variation with the serum lipids, PCSK9 levels and concomitant diseases on the ISR risk. The study included 109 ISR, and 82 Non-ISR patients, based on the results of coronary angiography. Genotypes were determined using the real-time PCR and serum PCSK9 levels were measured by ELISA technique. The rare G allele of PCSK9 E670G (p < 0.05), hyperlipidemia (HL) (p < 0.001), and type 2 diabetes (T2DM) (p < 0.01) were associated with increased risk for ISR. In hyperlipidemic conditions, the E670G-G allele was associated with hypercholesterolemia and a higher risk of ISR (p < 0.001), while the E670G-AA genotype has been associated with a high prevalence of T2DM and hypertension. In addition, diabetic ISRs had higher serum PCSK9 levels (p < 0.05) and the E670G-AA genotype was associated with increased levels of diabetes markers. Our results indicated that the unusual effects of both G allele and AA genotype of the PCSK9 E670G variation may be involved in the risk of ISR in association with concomitant metabolic diseases.
- 1 November 2020
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 138, 110379
Investigation of DFNB4 SLC26A4 mutation in patients with enlarged vestibular aquaduct
- 1 November 2020
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 138, 110379
Investigation of DFNB4 SLC26A4 mutation in patients with enlarged vestibular aquaduct